SCHEMBL8959797

SCHEMBL8959797

CC(=O)N1CC(=O)c2cc(F)ccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 6/20 0.60
HSD17B3 P37058 1/20 0.48
PARK7 Q99497 2/20 0.41
AVPR1A P37288 1/20 0.40
KIF11 P52732 1/20 0.39
KCNN4 O15554 1/20 0.38
KCNA3 P22001 1/20 0.38
TRPA1 O75762 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.36
MEN1 O00255 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
GABRA1 P14867 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL569327 0.87 NOTUM (0.60) NOTUMHSD17B3AVPR1AKIF11KCNN4
SCHEMBL5712023 0.81 NOTUM (0.62) NOTUMHSD17B3KCNN4KCNA3LMNA
SCHEMBL17369318 0.81 NOTUM (0.40) NOTUMPARK7SMN1; SMN2
SCHEMBL5712058 0.80 NOTUM (0.60) NOTUMHSD17B3KCNN4KCNA3GABRA1
SCHEMBL5712043 0.80 NOTUM (0.60) NOTUMHSD17B3KCNN4KCNA3MEN1
SCHEMBL11037023 0.80 NOTUM (0.60) NOTUMHSD17B3KCNN4KCNA3CYP2D6
SCHEMBL31394419 0.80 NOTUM (0.60) NOTUMHSD17B3KCNN4KCNA3MEN1
SCHEMBL5712014 0.79 NOTUM (0.58) NOTUMKCNN4KCNA3LMNAALDH1A1
SCHEMBL5712056 0.78 NOTUM (0.57) NOTUMHSD17B3CYP11B1CYP11B2LMNA
SCHEMBL1048074 0.75 NOTUM (1.00) NOTUMHSD17B3KCNN4KCNA3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2025-03-20 US disclosed
CN-117603121-A C (sp) of indol-3-one 3 ) Process for preparing-H aminated derivatives 温州医科大学 2024-02-27 CN disclosed
WO-2023008577-A1 RAS/RAF BINDING INHIBITOR COMPOUND 国立大学法人神戸大学 2023-02-02 WO disclosed
US-5494928-A FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1996-02-27 US disclosed
EP-0655440-A2 1-Aminoethylindoles F. HOFFMANN-LA ROCHE AG (CH) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND BRAF, RAF1, NRAS NOTUM 4253/4885HSD17B3 4169/4885PARK7 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.